2025 Was A Tough Year For US Biopharma IPOs, 2026 Is Still Up For Debate

Market Conditions Deteriorating As Valuations Dip

 
• By Mandy Jackson
  
The IPO class of 2025 is performing well relative to biopharma firms that went public in 2024 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business